id: fezolinetant
title: "Fezolinetant"
kind: intervention
summary: >-
  Fezolinetant is a neurokinin 3 (NK3) receptor antagonist and, per The
  Menopause Society's 2023 Nonhormone Therapy Position Statement, a
  first-in-class FDA-approved medication. The statement reports it as
  recommended for vasomotor symptoms at Level I evidence (good and consistent
  scientific evidence). This entry summarizes what the literature reports for
  navigation and is not medical advice.
evidence_strength: moderate
status: published
sources:
  - url: https://pubmed.ncbi.nlm.nih.gov/37252752/
    title: "The Menopause Society — 2023 Nonhormone Therapy Position Statement (Menopause, 2023; PMID 37252752)"
    publisher: The Menopause Society (Menopause journal)
    date: "2023"
    note: "NK3 receptor antagonist; first-in-class FDA-approved; Level I evidence for VMS."
signals:
  - sig-20260710-fezolinetant-mechanism
confidence: medium
first_seen: "2026-07-10"
last_updated: "2026-07-10"
notes: >-
  Subject is the specific drug fezolinetant. The entities registry has no
  dedicated id for it; it currently falls under the broad `non-hormonal-vasomotor`
  category entity (which lists "fezolinetant" among its aliases, kind:
  intervention). PROPOSED entities.yml addition: a dedicated `fezolinetant`
  intervention entry for cleaner navigation. Single source (2023 Nonhormone
  Therapy Position Statement), so confidence is medium; evidence_strength
  moderate reflects the statement's Level I grading, though the underlying
  trials/meta-analyses are not directly cited. Fezolinetant's use for vasomotor
  symptoms is cross-referenced on the `vasomotor-symptoms` symptom entry, kept
  distinct per profile (drug/intervention vs. the symptom it is studied for).